Strike three: Bristol-Myers’ third I/O shot at glioblastoma misses as Opdivo flops yet again on key endpoint

Bristol-Myers Squibb put out word Thursday morning that its third Phase III assault on brain cancer using its star PD-1 Opdivo failed the first endpoint, with no significant improvement in progression-free survival for patients who face grim odds.